Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This is a phase IV, double-blind, multicenter, randomized trial evaluating the efficacy and safety of two M3 receptors antagonists (Trospium Chloride and Darifenacin Hydrobromide) with one standard drug (Oxybutynin Chloride) for treatment of overactive bladder in individuals with spinal cord injury.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male or female patients, between 18 and 75 years of age. Female patients of childbearing potential* must have a negative urine pregnancy test result on the day of Screening Visit and practice a reliable method of contraception**
*A female is considered of childbearing potential unless she is:
Postmenopausal for at least 12 months prior to study drug administration;
Without a uterus and/or both ovaries; or
Has been surgically sterilized for at least 6 months prior to study drug administration.
**Reliable methods of contraception include:
Hormonal methods or intrauterine device in use at least 30 days prior to study drug administration;
Barrier methods plus spermicidal in use at least 14 days prior to study drug administration; or
Sexual abstinence as a lifestyle.
Patients with a neurogenic bladder and detrusor overactivity secondary to a spinal cord injury.
Patients with urinary incontinence (minimum of one occurrence per day) despite current treatment. [NOTE: Bladder emptying may be accomplished with straining, intermittent catheterization (IC), spontaneous micturition or leakage episodes.]
Patients with serum creatinine within normal limits and normal renal function
Patients on a stable dose (minimum one month) of concomitant medication for Neurogenic detrusor overactivity
Patients must have adequate cognitive function to understand the requirements of the study, including completing questionnaires and signing a written Informed Consent.
Female patients who are pregnant (positive urine pregnancy test), planning to become pregnant during the study period, breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control.
Patients with a history of transurethral sphincterotomy, bladder neck or prostatic resection, previous bladder surgery including myomectomy or augmentation cystoplasty.
Patients with chronic indwelling catheters.
Patients with, in the opinion of the Investigator, unstable or stable multiple sclerosis.
Patients with known, uncontrolled systemic disease.
Patients with evidence of recent alcohol/drug abuse.
Patients with urinary retention, gastrointestinal obstructive disorders or uncontrolled narrow-angle glaucoma.
Patients with contraindications to Trosec™, Enablex™ and Uromax®.
Patients who, in the opinion of the Investigator, have a significant condition or situation that may put the patient at significant risk, confound the study results, or interfere significantly with the patient's participation in the study.
Patients with a history of poor cooperation, non-compliance, or unreliability.
Patients currently participating in an investigational drug study or who have participated in an investigational drug study within 30 days of the Screening Visit.
Patients administered anticholinergics and/or antispasmodic drugs during the course of the study.
Patient with hepatic insufficiency.
Patient has been administered intravesical botulinum toxin within 6 months prior to the Screening Visit and/or is expected to receive intravesical botulinum toxin during the course of the study.
Patient has any medical condition that would interfere with the interpretation of the study results or the conduct of the study.
Spinal Cord Injuries
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System
Wounds and Injuries
Peripheral Nervous System Agents
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action